

Abeona Therapeutics Inc.

(ABEO-NASDAQ)

ABEO: Momentum Building for Zevaskyn®

Based on our probability adjusted DCF model that takes into account potential future revenues of pz-cel and selling a PRV, ABEO is valued at \$13.00/share. This model is highly dependent upon the continued clinical and commercial success of pz-cel and will be adjusted accordingly based on future results.

Current Price (03/18/26) \$4.76
Valuation **\$13.00**

OUTLOOK

On March 17, 2026, Abeona Therapeutics, Inc. (ABEO) announced financial results for the fourth quarter and full year ending December 31, 2025 and provided a business update. The company has thus far treated two patients with Zevaskyn®, one in the fourth quarter of 2025 and another in the first quarter of 2026. Additional patients have been biopsied and are expected to be treated in the coming weeks. Thus far, the company has identified over 100 patients that it believes are eligible for Zevaskyn treatment. In December 2025, the fourth Qualified Treatment Center (QTC) was brought on-board at The University of Texas Medical Branch (UTMB) in Galveston, TX. Abeona is hoping to have seven QTC's online before the end of 2026.

SUMMARY DATA

52-Week High \$7.23
52-Week Low \$4.17
One-Year Return (%) -7.75
Beta 1.13
Average Daily Volume (sh) 1,294,924

Shares Outstanding (mil) 54
Market Capitalization (\$mil) \$258
Short Interest Ratio (days) N/A
Institutional Ownership (%) 81
Insider Ownership (%) 7

Annual Cash Dividend \$0.00
Dividend Yield (%) 0.00

5-Yr. Historical Growth Rates
Sales (%) N/A
Earnings Per Share (%) N/A
Dividend (%) N/A

P/E using TTM EPS N/A
P/E using 2026 Estimate 3.4
P/E using 2027 Estimate 34.8

Risk Level
Type of Stock
Industry
Average
Small-Value
N/A

ZACKS ESTIMATES

Revenue (in millions of \$)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2025	0.0 A	0.4 A	0.0 A	5.4 A	5.8 A
2026	2.7 E	10.8 E	16.2 E	21.6 E	51.3 E
2027					143.0 E
2028					286.0 E

Earnings per Share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2025	-\$0.24 A	\$2.07 A	-\$0.10 A	-\$0.37 A	\$1.34 A
2026	-\$0.29 E	-\$0.14 E	-\$0.12 E	-\$0.06 E	-\$0.62 E
2027					\$0.44 E
2028					\$2.20 E

WHAT'S NEW

Business Update

Momentum Building for Zevaskyn®

Abeona Therapeutics, Inc. (ABEO) has successfully transitioned to a commercial-stage company following the April 2025 approval of Zevaskyn, although the early launch metrics thus far show that the company is still in the initial rollout phase. The company has treated two patients thus far, one in the fourth quarter of 2025 and another in the first quarter of 2026. Multiple patients have been biopsied this quarter and each is at a different manufacturing stage with treatment expected over the coming weeks.

We view 2026 as a process-validation year as management is focused on establishing treatment workflows that will lead to a steady increase in the number of treated patients as the year progresses. In December 2025, the company added a fourth Qualified Treatment Center (QTC) at The University of Texas Medical Branch (UTMB) in Galveston, TX to help support increased patient throughput and expand the company's geographic footprint.

During the conference call, management indicated that they have now identified > 100 patients that are potentially suitable for Zevaskyn treatment. Importantly, policies covering Zevaskyn have been published by all major commercial payers, including United Healthcare, Cigna, Aetna, Anthem, and Blue Cross and Blue Shield. The first patient treated for which the company has received payment (\$2.4M) was covered by Medicaid, so net revenues are expected to normalize over time as the payer mix begins to include commercially insured patients.

As 2026 continues, investors should continue to pay attention to biopsy volume growth, the time it takes for a patient to go from biopsy to treatment, the number of patients that the company is able to treat per quarter, how many patients are treated at each QTC per quarter, and the payer mix evolution. We believe the demand for Zevaskyn is there and as operational efficiencies continue to improve the number of patients treated, and the revenue recognized, will continue to increase as the year progresses.

Financial Update

On March 17, 2026, Abeona announced financial results for 2025. The company reported total revenue of \$5.8 million for the year ending December 31, 2025. The revenue consisted of \$3.4 million in license and other revenues and \$2.4 million in net product revenue. License and other revenues are driven by a clinical milestone reached under the October 2020 sublicense agreement with Taysha Gene Therapies for its investigational Rett syndrome gene therapy. The net product revenue is derived from the one patient treated with Zevaskyn in December 2025. That patient was covered by Medicaid, thus we anticipate revenues normalizing over time as patients covered by commercial insurers are treated. R&D expenses in 2025 were \$26.8 million compared to \$34.4 million for 2024. The decrease was primarily due to the FDA approval of Zevaskyn, which resulted in certain production costs being capitalized into inventory and engineering runs that are no longer classified as R&D. SG&A expenses in 2025 were \$65.0 million compared to \$29.9 million for 2024. The increase was primarily due to the commercial transition following Zevaskyn's approval, including \$18.6 million in personnel and stock-based compensation and \$2.3 million in direct commercialization costs.

Abeona exited 2025 with approximately \$191.4 million in cash, cash equivalents, and short-term investments. As of March 11, 2026, the company had approximately 57.1 million shares outstanding and, when factoring in stock options, restricted stock, and warrants, a fully diluted share count of approximately 70.2 million.

Conclusion

Abeona has entered the commercial stage with Zevaskyn, and while we believe the demand is there the company is still clearly in the operational buildout phase rather than the launch ramp phase. This year will be about repeatable execution in terms of patient identification, manufacturing, and treatment delivery. Investors should look for improved metrics in terms of number of patients treated, turnaround time from biopsy to treatment, and increased throughput at each of the QTCs. There are a lot of moving parts to coordinate, but as the company and each QTC get the procedures standardized we believe the launch ramp phase will begin to initiate toward the end of 2026 and into 2027. We pushed out revenue expectations slightly as we had underestimated the time necessary to reach an inflection point, and while this has caused a slight decrease to our valuation we are confident in the long-term story and would look at any near-term pullbacks in the stock as buying opportunities. Our valuation now stands at \$13 per share.


PROJECTED FINANCIALS

Abeona Therapeutics Inc.	2025 A	Q1 E	Q2 E	Q3 E	Q4 E	2026 E	2027 E	2028 E
ZEVASKYN™	\$2.4	\$2.7	\$10.8	\$16.2	\$21.6	\$51.3	\$143.0	\$286.0
License and other revenues	\$3.4	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Total Revenues	\$5.8	\$2.7	\$10.8	\$16.2	\$21.6	\$51.3	\$143.0	\$286.0
Cost of revenues	\$1.5	\$1.5	\$3.0	\$3.5	\$4.0	\$12.0	\$24.0	\$40.0
<i>Gross Margin</i>	74%	44%	72%	78%	81%	77%	83%	86%
Royalties	\$1.9	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Research & development	\$26.8	\$4.0	\$4.0	\$4.0	\$4.0	\$16.0	\$17.0	\$18.0
General & administrative	\$65.0	\$15.0	\$16.0	\$17.0	\$19.0	\$67.0	\$70.0	\$75.0
Operating Income	(\$89.4)	(\$16.3)	(\$9.2)	(\$8.3)	(\$5.4)	(\$43.7)	\$32.0	\$153.0
<i>Operating Margin</i>	-1536.9%	-603.7%	-85.2%	-51.4%	-25.0%	-85.2%	22.4%	53.5%
Non-Operating Expenses (Net)	\$160.7	\$2.0	\$2.0	\$2.0	\$2.0	\$8.0	\$0.0	\$1.0
Pre-Tax Income	\$71.3	(\$14.3)	(\$7.2)	(\$6.3)	(\$3.4)	(\$35.7)	\$32.0	\$154.0
Income Taxes	\$0.1	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$5.4	\$20.0
<i>Tax Rate</i>	0%	0%	0%	0%	0%	0%	17%	13%
Net Income	\$71.2	(\$14.3)	(\$7.2)	(\$6.3)	(\$3.4)	(\$35.7)	\$26.6	\$134.0
<i>Net Margin</i>	1223.1%	-	-	-	-	-	18.6%	46.9%
Reported EPS	\$1.34	(\$0.29)	(\$0.14)	(\$0.12)	(\$0.06)	(\$0.62)	\$0.44	\$2.20
Basic Shares Outstanding	53.0	49.8	52.5	54.2	55.0	58.0	60.0	61.0

Source: Zacks Investment Research, Inc.

David Bautz, PhD

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, David Bautz, PhD, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.

Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business. SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.